Phaseline

Targets › TRGC1

TRGC1 (T cell receptor gamma constant 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Constant region of T cell receptor (TR) gamma chain that participates in the antigen recognition. Gamma-delta TRs recognize a variety of self and foreign non-peptide antigens frequently expressed at the epithelial boundaries between the host and external environment, including endogenous lipids presented by MH-like protein CD1D and phosphoantigens presented by butyrophilin-like molecule BTN3A1. (UniProt, P0CF51)

Open in Phaseline: the race on TRGC1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Kansas Medical CenterEAGD T-cell infusion (Expanded/Activated Gamma Delta T-cells)
Gamma delta (γδ) T-cell immunotherapy enriched via α/β T-cell depletion
TRGC1, TRGC2Phase 1Acute Myeloid LeukemiaJan 2027

Conditions

Acute Myeloid Leukemia (1)

Modalities

other (1)

Companies

University of Kansas Medical Center (1)

Related targets

TRGC2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.